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We report a 60-year-old man with prostate cancer diagnosed during androgen replacement therapy 
(ART) for late onset hypogonadism after surgery for pituitary adenoma. He was refered to the department 
of urology since prostate specific antigen values were elevated after 6 months of ART. After the diagnosis of 
prostate cancer, ART was discontinued, and robot-asssited laparoscopic radical prostatectomy with pel吋c
lymphadenoctomy was performed. Pathological examination revealed Gl聞 onscore 4 + 5 prostate 
adenocarcinoma with seminal vesicle invasion and lymph node metastasis恒T3bNl). He has stayed 
biochemically and radiologically disease-free 33 months postoperatively. 
(Hinyokika Kiyo 64: 501 504, 2018 DOI: 10.14989/ActaUroリap64 12 501) 
























初診時検査所見：血算・生化学はPSA: 4.4 ng/ ml. 
LH 3. 19 mIU/ml (1. 26～10. 05), FSH 5. 32 mIU/ml 
(1. 37～13. 58），テストステロン 2.50 ng/ml (7. 50 



















502 泌尿紀要 64巻 12号 2018年
Fig. 1. MRI T2 showed tumor massively protruded 
from the c叩suleon right side in peripheral 













































れている.Endocrine society guideline 20 I 03）や EAU




























れている.EAU guidelines on male hypogonadism7）で
は， Gleason<8かつ， pTl-2かつ， PSA < 10 ng/rnl 
を満たす根治的前立腺全摘除術後の症例では術後l年
間の PSA低下を確認したのちに再開可能， Endocrine





Table I. Reports of patients wi出 LOH(late onset hypogonadism) syndrome who underwent ART was conducted 
after radical prostatectomy 
Study Year Number of Follow up (month) %pGs:::;;s Pre-ART %RMI %PSA ele、rationpatients PSA (ng/ml) 
Kaufman9) 2004 7 24 0.0 <O.I 14.3 0.0 
Agarwa!10) 2006 10 19 10.0 <O.I N.S. 0.0 
era1) 2009 57 13 7.0 0.005 0.0 0.0 
Pastuszak12) 2013 
Total 103 27.5 10.7 0.004 16.5 4.0 
Non-high risk 77 (74.8%) 28.1 0.0 0.004 0.0 0.0 
High risk* 26 (25.2%) 26.3 42.3 0.004 65.4 15.0 
pGS: pathological Gleason score, ART: testosterone replacement therapy, RMI: positive surgical margin. 
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